Latest Conference Articles

Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.

Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

See poll results highlighting the top gastrointestinal oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Oncology experts and AI advocates discuss insights about how AI can help manage tasks, keep up with evolving treatment practices, and improve patient care.

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Katie Goodman, RN, BSN, discusses the ways in which artificial intelligence can help speed up the pace of clinical trial accrual

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

Misty D. Shields, MD, PhD, discusses the modern role for prophylactic cranial irradiation in extensive-stage SCLC management.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Kashyap Patel MD, ABIM, BCMAS, discusses the present challenges with integrating AI tools into community practice.

Jim Chen, MD, discusses how artificial intelligence can aid community oncologists in providing optimal care.

Ruemu E. Birhiray, MD, discussed the advantages of using AI-based tools to enhance community-based clinical trials in oncology.

Brian P. Mulherin, MD, discusses using AI tools to improve the implementation of NGS in community oncology practice.

Brian P. Mulherin, MD, discusses how artificial intelligence is helping shape smarter cancer care.

AI-powered clinical decision support systems can help oncologists manage rising information demands without forfeiting autonomy in care delivery.

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.

Douglas Flora, MD, LSSBB, discusses how the use of artificial intelligence tools could improve patient screening and drug development in oncology.

Lalan Wilfong, MD, discusses the patient- and provider-facing implications that may result from renewed focus on improving care navigation in oncology.

Doug Flora, MD, FACC, LSSBB, explains how AI is transforming cancer care, urging oncologists to engage and guide its responsible use.